Sign Up Today and Learn More About Photys Therapeutics Stock
Invest in or calculate the value of your shares in Photys Therapeutics or other pre-IPO companies through EquityZen's platform.
Photys Therapeutics Stock (PHTH)
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.
About Photys Therapeutics Stock
Founded
2021
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Photys Therapeutics Press Mentions
Stay in the know about the latest news on Photys Therapeutics
Bifunctional kinase binding compounds and uses thereof
patents • Apr 02, 2025
Composés bifonctionnels de liaison à la kinase et leurs utilisations
patents • Apr 02, 2025
Bifunctional kinase binding compounds and uses thereof
patents • Apr 02, 2025
Photys licenses rights to Polymed’s IRAK-4 degrader
bioworld • Feb 23, 2025
Photys Therapeutics Enters into Exclusive License Agreement with Polymed for Phase 1-Ready IRAK4 Degrader, Furthering its Proximity-based Pipeline and Mission
globenewswire • Feb 20, 2025
Photys Therapeutics Management
Leadership team at Photys Therapeutics
Board of Directors
Lizzie Ngo
Board of Directors
Otello Stampacchia
Join now and verify your accreditation status to gain access to:
- Photys Therapeutics Current Valuation
- Photys Therapeutics Stock Price
- Photys Therapeutics Management
- Available deals in Photys Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Photys Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Photys Therapeutics Revenue and Financials
- Photys Therapeutics Highlights
- Photys Therapeutics Business Model
- Photys Therapeutics Risk Factors
- Photys Therapeutics Research Report from SACRA Research
Trading Photys Therapeutics Stock
How to invest in Photys Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Photys Therapeutics through EquityZen funds. These investments are made available by existing Photys Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Photys Therapeutics stock?
Shareholders can sell their Photys Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
